⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Parthenolide
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-30 — Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization: Preclinical scleroderma model: parthenolide bound Ero1L and stabilized mitochondria-associated ER membranes, reducing cellular senescence and fibrosis markers — mechanistic animal/cell evidence, no human outcome data. [animal-model] (novelty: 3)